Compare
LENSAR, Inc. vs CVRx, Inc. vs Apyx Medical Corp vs Carlsmed, Inc.
| Latest fiscal year | LENSAR, Inc. LNSR | CVRx, Inc. CVRX | Apyx Medical Corp APYX | Carlsmed, Inc. CARL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $58.44M | $56.65M | $52.84M | $50.51M |
| Revenue growth (YoY) | +9.2% | +10.4% | +9.9% | +85.9% |
| Gross margin | 46.4% (computed) | 85.3% | 62.5% | 75.3% |
| Operating margin | -42.1% | -90.5% | -12.2% | -60.5% |
| Net margin | -58.7% | -94.1% | -21.2% | -58.7% |
| Net income | -$34.28M | -$53.31M | -$11.21M | -$29.63M |
| EPS (Diluted) | -$2.87 | -$2.04 | n/a | -$2.12 |
| Operating cash flow | -$14.83M | -$40.17M | -$8.00M | -$28.98M |
| Free cash flow | -$14.91M | -$40.75M | -$9.12M | -$29.62M |
| Cash & equivalents | $12.97M | $75.71M | $31.74M | $85.79M |
| Total assets | $71.43M | $104.79M | $66.84M | $130.12M |
| Total liabilities | $83.67M | $65.47M | $52.01M | $31.25M |
| Shareholders' equity | -$26.02M | $39.32M | $14.54M | $98.87M |
| Return on year-end equity | n/a | -135.6% | -77.1% | -30.0% |
| Shares outstanding | 11.99M | 26.31M | 41.79M | 26.60M |
Revenue, most recent five fiscal years
| Fiscal year | LENSAR, Inc. | CVRx, Inc. | Apyx Medical Corp | Carlsmed, Inc. |
|---|---|---|---|---|
| Latest | $58.44M Ended 2025-12-31 | $56.65M Ended 2025-12-31 | $52.84M Ended 2025-12-31 | $50.51M Ended 2025-12-31 |
| 1 year earlier | $53.49M Ended 2024-12-31 | $51.29M Ended 2024-12-31 | $48.10M Ended 2024-12-31 | $27.16M Ended 2024-12-31 |
| 2 years earlier | $42.16M Ended 2023-12-31 | $39.30M Ended 2023-12-31 | $52.35M Ended 2023-12-31 | n/a |
| 3 years earlier | $35.36M Ended 2022-12-31 | $22.47M Ended 2022-12-31 | $44.51M Ended 2022-12-31 | n/a |
| 4 years earlier | $34.46M Ended 2021-12-31 | $13.04M Ended 2021-12-31 | $48.52M Ended 2021-12-31 | n/a |